Therapeutic Effect of Quercetin and the Current Treatment of Erosive and Atrophic Oral Lichen Planus

Status

UNKNOWN

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01375101

Enrollment

Registered

2011-06-17

Start date

2010-04-30

Completion date

2011-09-30

Last updated

2011-07-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrophic Oral Lichen Planus, Erosive Oral Lichen Planus

Keywords

lichen planus, quercetin

Brief summary

Lichen planus (LP) is a common chronic inflammatory mucocutaneous disease with an immunologic etiology ,which has number of different clinical forms. Alternative natural or herbal origine drugs with antioxidant and anti-inflammatory properties have been used individually or in combination with systemic corticosteroids in order to decrease adverse drug reactions. This study was conducted to evaluate the effect of quercetin on treatment of erosive -atrophic lesions of oral lichen planus (OLP).

Interventions

DRUGplacebo

The patient is directed to use placebo capsule two times a day, ,until the one mouth

DRUGQuercetin

The patient is directed to digest quercetin hydrate capsule two times a day,until one mouth

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

12 Years to 60 Years

Healthy volunteers

Inclusion criteria

* confirmation of clinical diagnosis of Atrophic and erosive lichen planus by histological examination * two weeks wash out periods after the last treatment * having the experience of atrophic and erosive lesion greater than 1 cm having the experience of pain and burning greater than 3.5 in VAS Score

Exclusion criteria

* confirmation of dysplasia and malignancy in histologic examination * confirmation of lichenoid reaction in histologic examination * pregnancy and breast feeding * using fluorokinolon and cyclosporin which interact with quercetin

Design outcomes

Primary

Measure	Time frame	Description
the effects of this Drug on OLP measured with VAS scale for pain and evaluation of intensity of lesions.	2 months	In the present work the Analogical Visual Scale is used TO evaluate pain,and we also record the intensity of lesions weekly and any side effect of this Drug

Countries

Iran

Contacts

Primary Contactmaryam amirchaghmaghi, assistant professor

amirchakhmaghim@mums.ac.ir0098-0511889201

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 5, 2026